



SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31st December ' 2021.

Rs. In Lakhs

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For 9 Months Ended		For the year ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	Audited
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	39,158.53	30,098.83	27,493.32	95,637.49	75,055.37	1,00,971.85
	Other Income	927.43	3,833.50	484.29	5,339.22	1,093.88	1,423.70
	Total income	40,085.96	33,932.33	27,977.61	1,00,976.71	76,149.25	1,02,395.55
2	Expenses						
	a) Cost of materials consumed	11,847.97	11,885.90	7,975.82	32,917.83	22,294.04	31,031.50
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	96.07	(2,628.34)	(1,354.57)	(4,041.18)	(1,235.58)	(837.30)
	d) Employee benefits expense	2,500.87	2,319.43	2,134.71	6,936.19	5,972.03	7,623.30
	e) R & D expense	218.85	366.94	265.85	821.03	955.12	1,105.75
	f) Finance costs	74.17	117.51	191.03	404.23	727.34	914.37
	g) Depreciation and amortisation expenses	1,050.60	917.70	875.75	2,867.63	2,332.11	3,163.58
	h) Manufacturing Expenses	4,625.81	4,373.88	3,551.28	12,884.52	8,910.63	13,378.94
	i) Other Expenses	1,266.16	1,603.51	1,186.80	3,877.14	3,476.23	4,617.49
	Total expenses	21,680.50	18,956.53	14,826.67	56,667.39	43,431.92	60,997.63
3	Profit before exceptional items & Tax (1-2)	18,405.46	14,975.80	13,150.94	44,309.32	32,717.33	41,397.92
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	18,405.46	14,975.80	13,150.94	44,309.32	32,717.33	41,397.92
6	Tax Expenses						
	a) Current tax	4,620.66	3,278.01	3,444.22	10,615.02	8,336.86	10,171.51
	b) Deferred tax	85.27	178.03	(56.76)	330.89	(39.01)	361.72
7	Net Profit/ (Loss) for the period/year(5-6)	13,699.53	11,519.76	9,763.48	33,363.41	24,419.48	30,864.69
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(27.95)	(27.98)	(27.33)	(83.89)	(81.98)	(111.85)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	7.03	7.05	6.87	21.11	20.63	28.15
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(20.92)	(20.93)	(20.46)	(62.78)	(61.35)	(83.70)
9	Total Comprehensive Income for the period (7+8)	13,678.61	11,498.83	9,743.02	33,300.63	24,358.13	30,780.99
10	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00
11	Other Equity	-	-	-	-	-	1,03,972.68
12	Earning Per Share (EPS)-Face value of Rs.1/- each						
	a) Basic	5.38	4.53	3.84	13.11	9.59	12.12
	b) Diluted	5.38	4.53	3.84	13.11	9.59	12.12
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

PART - II		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For 9 Months Ended		For the year ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	Audited
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	39,158.53	30,098.83	27,493.32	95,637.49	75,055.37	1,00,971.85
	Other Income	6,468.51	504.11	484.29	7,550.91	1,093.88	1,423.70
	Total income	45,627.04	30,602.94	27,977.61	1,03,188.40	76,149.25	1,02,395.55
2	Expenses						
	a) Cost of materials consumed	11,847.97	11,885.90	7,975.82	32,917.83	22,294.04	31,031.50
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	96.07	(2,628.34)	(1,354.57)	(4,041.18)	(1,235.58)	(837.30)
	d) Employee benefits expense	2,500.87	2,319.43	2,134.71	6,936.19	5,972.03	7,623.30
	e) R & D expense	218.85	366.94	265.85	821.03	955.12	1,105.75
	f) Finance costs	74.17	117.51	191.03	404.23	727.34	914.37
	g) Depreciation and amortisation expense	1,050.60	917.70	875.75	2,867.63	2,332.11	3,163.58
	h) Manufacturing Expenses	4,625.81	4,373.88	3,551.28	12,884.52	8,910.63	13,378.94
	i) Other Expenses	1,266.91	1,603.52	1,187.73	3,878.61	3,480.12	4,621.60
	Total expenses	21,681.25	18,956.54	14,827.60	56,668.86	43,435.81	61,001.74
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	23,945.79	11,646.40	13,150.01	46,519.54	32,713.44	41,393.81
4	Add : Share of profit/(Loss) of Associates.	-	1,746.33	1,599.98	4,111.23	3,507.00	5,373.60
5	Profit before exceptional items , Tax (3+4)	23,945.79	13,392.73	14,749.99	50,630.77	36,220.44	46,767.41
6	Exceptional Items	-	-	-	-	-	-
7	Profit before Tax (5-6)	23,945.79	13,392.73	14,749.99	50,630.77	36,220.44	46,767.41
8	Tax Expenses						
	a) Current tax	6,843.36	3,516.22	3,444.22	13,075.93	8,336.86	10,171.51
	b) Deferred tax	1,095.53	178.03	(56.76)	1,341.15	(39.01)	361.72
9	Net Profit/ (Loss) for the period/year(7-8)	16,006.90	9,698.48	11,362.53	36,213.69	27,922.59	36,234.18
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss	(27.95)	(27.98)	(27.33)	(83.89)	(81.98)	(111.85)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	7.03	7.05	6.87	21.11	20.63	28.15
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(20.92)	(20.93)	(20.46)	(62.78)	(61.35)	(83.70)
11	Total Comprehensive Income for the period (9 + 10)	15,985.98	9,677.55	11,342.07	36,150.91	27,861.24	36,150.48
12	Paid-up equity share capital Face Value of the Share	2,545.65 Re. 1.00	2,545.65 Re. 1.00	2,545.65 Re. 1.00	2,545.65 Re. 1.00	2,545.65 Re. 1.00	2,545.65 Re. 1.00
13	Other Equity	-	-	-	-	-	1,15,535.18
14	Earning Per Share (EPS)- (Face value of Rs. 1/- each)						
	a) Basic -	6.29	3.81	4.46	14.23	10.97	14.23
	b) Diluted	6.29	3.81	4.46	14.23	10.97	14.23
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

- Notes**
- 1)** The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8 th Feb,2022 . The above results have been subjected to limited review by the statutory auditors of the company
 - 2)** The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3)** The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma,Inc.,USA.
 - 4)** The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 2.00 per equity share (200% of Face value of Rs.1.00), totalling to Rs. 3.00 per equity share (300% of Face value of Rs. 3.00 each) for the financial year 2021-22.
 - 5)** The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 6)** The COVID-19 continuous to impact the business and research operations in India and our Wholly Owned Subsidiary , Suven Pharma , Inc., USA. Apart from the above the shortage or non- availability of vessels leading to delay in shipments , increase in transportation and distribution costs and timely non availability of materials with increase in materials costs are impacting our operations and profitability.
 - 7)** The other Income (Standalone figures for Q2-2021-22) includes an amount of Rs.3329.39 Lacs pertaining to the Dividends received from our Subsidiary.And also the Current tax (Standalone figures) includes an amount of Rs.491.72 lacs tax paid on Such Dividend by our subsidiary.
 - 8)** The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to \$35.00 Mn) in M/s Rising pharma Holdings, Inc., USA on 13 th Dec,2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital , a leading global alternative investment firm in USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of \$ 41.555 Mn and a stake valued at \$15.803 Mn in Raisin Aggregators L.P. Accordingly , Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Dec'2021
 - 9)** The Board has in today's meeting held on 8th February, 2022, given its in-principle approval to evaluate the acquisition opportunity of Casper Pharma Pvt. Ltd. An SEZ company in Hyderabad engaged in Formulations. The Company will evaluate the proposal subject to financial, tax and legal due diligence to finalize the definitive agreements.
 - 10)** The corresponding previous period figures have been regrouped/reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD

Place : Hyderabad
Date : 8th Feb ' 2022

VENKAT JASTI
Chairman & MD
DIN: 00278028